Patents Examined by Marianne P. Allen
  • Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia
    Patent number: 10239926
    Abstract: As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 26, 2019
    Assignee: The University of Vermont and State Agriculture College
    Inventor: Jeffrey Spees
  • Highly concentrated formulations of soluble Fc receptors
    Patent number: 10226504
    Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: March 12, 2019
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl
  • HGF preparation suitable for treatment of neurological disorders
    Patent number: 10213485
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 26, 2019
    Assignee: KRINGLE PHARMA INC.
    Inventors: Kazuhiro Fukuta, Hayao Inoue
  • Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (EGF)
    Patent number: 10203343
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (EGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 12, 2019
    Assignee: CELLTREND GMBH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
    Patent number: 10202459
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 12, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • Anti-IGF antibodies
    Patent number: 10179810
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Stabilized insulin-like growth factor polypeptides
    Patent number: 10167329
    Abstract: This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 1, 2019
    Assignee: Novartis AG
    Inventors: Mara Fornaro, Thomas Huber, Mauro Zurini
  • Methods for treating metabolic disorders using FGF
    Patent number: 10159711
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 25, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 10160804
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 25, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark Litton, John Latham
  • Methods for treating vascular leak syndrome and cancer
    Patent number: 10150811
    Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: December 11, 2018
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Kevin Peters, Robert Shalwitz
  • Modified bovine G-CSF polypeptides and their uses
    Patent number: 10138283
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 27, 2018
    Assignees: AMBRX, INC., ELANCO US INC.
    Inventors: Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Ho, Peter C. Canning
  • Human CDR-grafted antibody and antibody fragment thereof
    Patent number: 10131711
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: November 20, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
    Patent number: 10112998
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: October 30, 2018
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof
    Patent number: 10106588
    Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 23, 2018
    Assignee: Trustees of Tufts College
    Inventor: Ira M. Herman
  • Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
    Patent number: 10106614
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Daltons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: October 23, 2018
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
    Patent number: 10100112
    Abstract: The present invention relates to inhibitors of the expression and/or activity of LIF for the treatment of cancer. Particularly, the present invention provides an in vitro method for designing a customized therapy for a patient suffering from cancer comprising (a) quantifying the expression levels of LIF in said patient, and (b) comparing said expression levels with control levels, wherein if the expression levels of LIF in said patient are greater than the control values, then an inhibitory agent of LIF is administered to said patient.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 16, 2018
    Assignees: Fundacio Privada Institutcio Catalana de Recerca I Estudis Avancats (ICREA), Fundacio Privada Institut D'Investigatio Oncologica Vall De'Hebron (VHIO), Fundacio Privada Institut de Recerca Hospital Universitatri Vall Hebron (IR-HUVH)
    Inventors: Joan Seoane Suarez, Silvia Penuelas Prieto, José Baselga Torres
  • Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
    Patent number: 10100110
    Abstract: The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: October 16, 2018
    Assignee: Ablynx, N.V.
    Inventors: Joost Alexander Kolkman, Hilde Adi Pierrette Revets, Jo Vercammen, Augustinus Antonius Maria Silvester van Dongen
  • Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
    Patent number: 10100117
    Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: October 16, 2018
    Assignee: National Research Council of Canada
    Inventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
  • Antibodies to HGF and compositions containing
    Patent number: 10100108
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: October 16, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Benjamin H. Dutzar, Katie Anderson, Brian R. Kovacevich, Andrew L. Feldhaus, John Latham, Leon F. Garcia-Martinez
  • Anti-PDGF-B antibodies and methods of use
    Patent number: 10087246
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser